BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, March 21, 2026
Home » Topics » Analysis and data insight

Analysis and data insight
Analysis and data insight RSS Feed RSS

Financial line chart

Neurological diseases index remained flat in August

Sep. 8, 2020
By Peter Winter
In a relatively light news flow for the group last month, the gainers and decliners in the BioWorld Neurological Diseases index canceled themselves out during August, with the result that the price-weighted index closed relatively flat and, despite briefly moving into positive territory in July, its value is down 4% for the year.
Read More

ICYMI: Week in review, Aug. 31-Sept. 4, 2020

Sep. 8, 2020
A quick look back at top stories.
Read More

Records already set, but the money keeps rolling in for biopharma

Sep. 4, 2020
By Karen Carey
The biopharma industry has raised a total of about $88 billion so far in 2020, the most ever for a single year, with four months to go. It hit the record in July when it surpassed the $68.4 billion raised in 2015.
Read More

Money raised by biopharma: 2020 vs. 2019

Sep. 4, 2020
Total raised in public, private and other financings of biopharma companies, comparing 2020 vs. 2019.
Read More

Biopharma money raised: Jan. 1-Sept. 3, 2020

Sep. 4, 2020
Year-to-date money raised in public, private and other financings of biopharma companies.
Read More
Hand holding IPO, financial icons

Biopharma money raised by quarter in 2020 (US$M)

Sep. 4, 2020
Biopharma money raised to-date and by quarter in 2020, including public, private and other financings.
Read More

BioWorld and Nasdaq stock indices

Sep. 4, 2020
These graphs compare the performance of the biotech stocks for all of 2020 using the BioWorld Stock Indicator and the Nasdaq Biotech Index.
Read More

Biggest gainers and losers for the week of Aug. 31-Sept. 4, 2020

Sep. 4, 2020
The top 10 biopharma stock gainers and losers for the week.
Read More

Med-tech gainers and losers for Aug. 31 to Sept. 4, 2020

Sep. 4, 2020
The top 10 med-tech stock gainers and losers for the week.
Read More
Microscope and coronavirus illustration

Beyond the noise, biopharma battles on with science for COVID-19

Sep. 1, 2020
By Karen Carey
As 2020 approaches its last quarter, scientists around the globe continue their all-consuming efforts to find effective therapeutics and vaccines to fight the deadly COVID-19 pandemic, which currently has a 3.35% fatality rate and has been plaguing the world for more than half a year. While the fight rages on, people are growing weary of political posturing and community debates. They face a serious conundrum of how to best protect those vulnerable to the virus, while still considering the psychological and economic impacts of societal lockdowns.
Read More
Previous 1 2 … 248 249 250 251 252 253 254 255 256 … 304 305 Next

Popular Stories

  • Today's news in brief

    BioWorld
  • Art concept for targeting the brain

    Precision psychiatry beyond, or before, biomarkers

    BioWorld
    There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
  • MRI image brain on black background

    ADPD 2026: Can we prevent dementia? Scientists quantify it

    BioWorld
    Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
  • First-in-class POLG activator restores mtDNA across mutations

    BioWorld Science
    Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for March 17, 2026
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing